Delaying the Onset of Nearsightedness Until Treatment Study (DONUT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jeffrey J Walline, OD PhD
- Phone Number: 6142476840
- Email: walline.1@osu.edu
Study Contact Backup
- Name: Lisa A Jordan, PhD
- Phone Number: 6142477321
- Email: jordan.646@osu.edu
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 6-11 years
Refractive error measured in spherical equivalent, one eye meets criterion
- 6 years old: 0.50 to +0.38
- 7 years old: 0.50 to +0.25
- 8-11 years old: 0.50 to plano
- Anisometropia: spherical equivalent <1.50 D
- Astigmatism: <1.50 in both eyes
- Myopia: Less myopic than -0.74 D, both eyes
Exclusion Criteria:
● Myopic
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 0.01% Atropine
0.01% atropine eye drops
|
eye drops to be administered once daily
|
|
Active Comparator: 0.03% Atropine
0.03% atropine eye drops
|
eye drops to be administered once daily
|
|
Active Comparator: 0.05% atropine
0.05% atropine eye drops
|
eye drops to be administered once daily
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compliance percentage
Time Frame: 30 days
|
A comparison of the compliance percentage with eye drop administration
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Jeffrey J Walline, OD PhD, Ohio State University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Refractive Errors
- Myopia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Adjuvants, Anesthesia
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Mydriatics
- Atropine
Other Study ID Numbers
Other Study ID Numbers
- DONUT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.